Alyeska Investment Group L.P. lifted its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 38.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 984,077 shares of the company's stock after acquiring an additional 273,920 shares during the quarter. Alyeska Investment Group L.P. owned 1.54% of Larimar Therapeutics worth $3,808,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in LRMR. China Universal Asset Management Co. Ltd. bought a new stake in Larimar Therapeutics during the fourth quarter valued at $52,000. Aquatic Capital Management LLC bought a new stake in shares of Larimar Therapeutics during the 4th quarter valued at about $70,000. Virtu Financial LLC acquired a new stake in Larimar Therapeutics during the third quarter worth about $71,000. SG Americas Securities LLC lifted its holdings in Larimar Therapeutics by 35.1% in the fourth quarter. SG Americas Securities LLC now owns 19,391 shares of the company's stock worth $75,000 after acquiring an additional 5,042 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Larimar Therapeutics by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 19,657 shares of the company's stock valued at $76,000 after acquiring an additional 6,701 shares during the period. 91.92% of the stock is currently owned by institutional investors.
Larimar Therapeutics Price Performance
Shares of NASDAQ:LRMR opened at $2.69 on Tuesday. The stock has a market cap of $172.24 million, a price-to-earnings ratio of -2.34 and a beta of 0.93. Larimar Therapeutics, Inc. has a 12 month low of $1.61 and a 12 month high of $11.20. The stock's 50 day moving average price is $2.36 and its 200 day moving average price is $4.17.
Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). On average, sell-side analysts expect that Larimar Therapeutics, Inc. will post -1.15 EPS for the current year.
Wall Street Analyst Weigh In
Several analysts recently issued reports on LRMR shares. Truist Financial initiated coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They issued a "buy" rating and a $18.00 price target on the stock. Citigroup restated a "buy" rating on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Robert W. Baird cut their price objective on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 25th. HC Wainwright upped their target price on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, March 25th. Finally, Guggenheim restated a "buy" rating and issued a $26.00 price target on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Larimar Therapeutics presently has an average rating of "Buy" and an average price target of $19.63.
View Our Latest Research Report on Larimar Therapeutics
Larimar Therapeutics Company Profile
(
Free Report)
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Larimar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.
While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
